Adaptimmune Therapeutics PLC Sponsored ADR
(NASDAQ : ADAP)

( )
ADAP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.86%122.371.1%$687.52m
GILDGilead Sciences, Inc.
-1.28%80.170.9%$652.57m
AMGNAmgen Inc.
-1.33%180.531.1%$453.70m
BIIBBiogen Inc.
-2.83%328.551.2%$418.30m
REGNRegeneron Pharmaceuticals, Inc.
-0.05%432.762.7%$322.07m
VRTXVertex Pharmaceuticals Incorporated
-2.31%151.061.9%$219.47m
INCYIncyte Corporation
-0.62%113.482.5%$198.97m
ALXNAlexion Pharmaceuticals, Inc.
-2.75%135.201.9%$188.62m
ILMNIllumina, Inc.
0.80%211.553.5%$133.98m
ALNYAlnylam Pharmaceuticals, Inc
0.76%115.5710.7%$131.21m
EXELExelixis, Inc.
-0.70%26.986.5%$126.80m
BLUEBluebird Bio, Inc.
-1.54%140.3517.3%$119.91m
SRPTSarepta Therapeutics, Inc.
-0.91%51.4716.9%$110.18m
BMRNBioMarin Pharmaceutical Inc.
-1.47%86.464.4%$109.02m
CLVSClovis Oncology, Inc.
-2.49%75.5716.5%$96.52m

Company Profile

Adaptimmune Therapeutics Plc is a clinical stage biopharmaceutical company, which focuses on novel cancer immunotherapy products based on T-cell receptor platform. Its TCR platform targets NY-ESO-1 cancer antigen. The company was founded in December 2014 and is headquartered in Oxford, the United Kingdom.